Valproate is an anticonvulsant medication used primarily to treat epilepsy, bipolar disorder, and migraine headaches. It has been available since the late 1970s and remains one of the most widely prescribed neurological medications in the world, sold under brand names including Depakote, Depakene, and Depacon. While effective across several conditions, valproate carries serious risks, particularly during pregnancy, that have led to increasingly strict prescribing rules.
Conditions Valproate Treats
All valproate products are FDA-approved for treating seizures, making epilepsy the medication’s core use. Certain formulations are also approved for two additional conditions: treating manic or mixed episodes in bipolar disorder, and preventing migraine headaches. It is one of only four FDA-approved medications for migraine prevention in the United States, alongside topiramate, propranolol, and timolol.
For migraine prevention, the results are meaningful but not dramatic. In clinical trials, roughly 44% to 65% of patients experienced at least a 50% reduction in migraine frequency, compared with about 18% to 21% of those taking a placebo. One large trial found that patients taking valproate went from an average of 4.4 migraine attacks per month down to about 3.2. Another study of 29 patients saw the average number of attacks drop from 15.6 to 8.8 over the treatment period. These numbers show real benefit, but they also mean a substantial number of people won’t respond.
How Valproate Works in the Brain
Valproate increases levels of GABA, a chemical messenger that calms nerve activity in the brain. It does this in two ways: slowing the breakdown of GABA and boosting its production. The result is more of this calming signal available between nerve cells. Valproate does not attach directly to GABA receptors the way some other medications do. Instead, it changes the overall supply.
Beyond GABA, research in animal models suggests valproate also affects ion channels (the tiny gates that control electrical signals in nerve cells), stress hormones, and signaling pathways inside cells. This broad range of effects likely explains why it works across such different conditions, from seizures to mood episodes to migraine.
Different Formulations
Valproate comes in several forms that are chemically related but differ in how the body absorbs them. Valproic acid (Depakene) was the original version, approved in 1978. Divalproex sodium (Depakote) followed in 1986 as an enteric-coated formulation designed to be gentler on the stomach. An extended-release version, Depakote ER, allows once-daily dosing. There is also an injectable form, valproate sodium (Depacon), for situations where a patient cannot take pills.
Valproic acid is metabolized more rapidly than divalproex sodium, which means higher doses are sometimes needed to reach the same therapeutic level. Clinical comparisons show a trend toward more nausea and overall gastrointestinal side effects with valproic acid, though discontinuation rates between the two have been similar in studies.
Common Side Effects
Weight gain is one of the most frequently reported concerns with long-term valproate use, and patients should be aware of it before starting treatment. Other common side effects include nausea, tremor, drowsiness, and hair thinning or hair loss. Some people also experience dizziness or difficulty concentrating, particularly when first starting the medication or after a dose increase.
In women, there has been ongoing discussion about a possible link between valproate and polycystic ovary syndrome (PCOS), a hormonal condition that can affect periods, fertility, and metabolism. Women with epilepsy appear to have higher rates of polycystic ovaries in general, but reliable data specifically tying this to valproate (rather than to epilepsy itself) remain limited.
Serious Risks
Valproate carries three black box warnings from the FDA, the most serious type of safety alert.
The first is liver damage. Fatal liver failure has occurred in patients taking valproate, most often within the first six months of treatment. Children under two years old face the highest risk, especially those taking multiple seizure medications or those with underlying metabolic conditions. Patients with a specific inherited mitochondrial disorder (mutations in the POLG gene) are at particular risk. Early warning signs include unusual tiredness, weakness, facial swelling, loss of appetite, and vomiting.
The second warning involves pancreatitis, an inflammation of the pancreas that can become life-threatening. Cases have been reported in both children and adults, sometimes shortly after starting the medication and sometimes after years of use. Severe abdominal pain, nausea, and vomiting warrant immediate medical attention.
The third, and perhaps most consequential, warning concerns pregnancy.
Pregnancy and Reproductive Risks
Valproate poses one of the highest risks of birth defects among all commonly prescribed medications. A meta-analysis found that 10.7% of children exposed to valproate in the womb develop major congenital malformations. That is roughly 1 in 9 pregnancies, a rate substantially higher than the general population or most other seizure medications.
The harm extends beyond structural birth defects. A large prospective study tracking children to age six found that those exposed to valproate before birth had IQ scores 7 to 10 points lower on average compared with children exposed to other antiepileptic medications. The cognitive effects were broad, affecting language, nonverbal reasoning, memory, and executive function.
These risks have prompted regulators to impose strict prescribing rules. In the UK, updated guidance from the Commission on Human Medicines now requires that valproate not be started in any new patient, male or female, under 55 years of age unless two independent specialists confirm there is no other effective or tolerated treatment, or that reproductive risks clearly do not apply. This rule reflects growing concern that valproate may also affect sperm quality, though the evidence for male reproductive harm is less established than for pregnancy.
Blood Monitoring While Taking Valproate
Valproate requires regular blood tests, particularly in the early months. Liver function tests should be checked before starting the medication and at frequent intervals during the first six months. A complete blood count, clotting tests, and ammonia levels are also checked at baseline and periodically thereafter.
For epilepsy, the accepted therapeutic blood level is between 50 and 100 mcg/mL. Staying within this range helps balance seizure control against side effects. When levels climb too high, one notable risk is thrombocytopenia, a drop in platelet count that impairs blood clotting. Research has identified a threshold where the “free” (unbound) concentration of valproate in the blood exceeds roughly 14.7 mcg/mL as the point where platelet problems become significantly more likely. For migraine prevention, there is no established therapeutic blood level, and dosing tends to be guided by clinical response and tolerability rather than lab values.
Typical doses for migraine prevention range from 500 to 1,500 mg per day, while doses for epilepsy and bipolar disorder vary based on weight, other medications, and individual response. Dose adjustments are common in the first weeks as blood levels are checked and side effects are assessed.